SEARCH

SEARCH BY CITATION

References

  • 1
    Bolden JE,Peart MJ,Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 76984.
  • 2
    Minucci S,Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 3851.
  • 3
    Plumb JA,Finn PW,Williams RJ,Bandara MJ,Romero MR,Watkins CJ,La Thangue NB,Brown R. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003; 2: 7218.
  • 4
    Qian X,LaRochelle WJ,Ara G,Wu F,Petersen KD,Thougaard A,Sehested M,Lichenstein HS,Jeffers M. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 2006; 5: 208695.
  • 5
    Duan J,Friedman J,Nottingham L,Chen Z,Ara G,Van Waes C. Nuclear factor-κB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2007; 6: 3750.
  • 6
    Tumber A,Collins LS,Petersen KD,Thougaard A,Christiansen SJ,Dejligbjerg M,Jensen PB,Sehested M,Ritchie JW. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer growth in vitro and in vivo. Cancer Chemother Pharmacol 2007; 60: 27583.
  • 7
    RiesLAG,HarkinsD,KrapchoM,MariottoA,MillerBA,FeuerEJ,CleggL,EisnerMP,HornerMJ,HowladerN,HayatM,HankeyBF, et al., eds. SEER cancer statistics review, 1975–2003. Bethesda, MD: National Cancer Institute. Available at http://seer.cancer.gov/csr/1975_2003/.
  • 8
    Hanahan D,Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 5770.
  • 9
    Brehmer B,Biesterfeld S,Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. Prostate Cancer Prostatic Dis 2003; 6: 21722.
  • 10
    Lichtinghagen R,Musholt PB,Lein M,Romer A,Rudolph B,Kristiansen G,Hauptmann S,Schnorr D,Loening SA,Jung K. Different mRNA and protein expression of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. Eur Urol 2002; 42: 398406.
  • 11
    Miyagi M,Aoyagi K,Kato S,Shirouzu K. The TIMP-1 gene transferred through adenovirus mediation shows a suppressive effect on peritoneal metastases from gastric cancer. Int J Clin Oncol 2007; 12: 1724.
  • 12
    Ramer R,Eichele K,Hinz B. Upregulation of tissue inhibitor of matrix metalloproteinase-1 confers the anti-invasive action of cisplatin on human cancer cells. Oncogene 2007; 26: 58227.
  • 13
    Hamroun D,Kato S,Ishioka C,Claustres M,Beroud C,Soussi T. The UMD TP53 database and website: update and revisions. Hum Mutat 2006; 27: 1420.
  • 14
    Sigal A,Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000; 60: 678893.
  • 15
    Gurova KV,Rokhlin OW,Budanov AV,Burdelya LG,Chumakov PM,Cohen MB,Gudkov AV. Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Cancer Res 2003; 63: 290512.
  • 16
    Perner S,Demichelis F,Beroukhim R,Schmidt FH,Mosquera JM,Setlur S,Tchinda J,Tomlins SA,Hofer MD,Pienta KG,Kuefer R,Vassella R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostat cancer. Cancer Res 2006; 66: 833741.
  • 17
    Rostad K,Mannelqvist M,Halvorsen OJ,Oyan AM,Bo TH,Stordrange L,Olsen S,Haukaas SA,Lin B,Hood L,Jonassen I,Akslen LA, et al. ERG upregulation and related ETS transcription factors in prostate cancer. Int J Oncol 2007; 30: 1932.
  • 18
    Tomlins SA,Rhodes DR,Perner S,Dhanasekaran SM,Mehra R,Sun XW,Varambally S,Cao X,Tchinda J,Kuefer R,Lee C,Montie JE, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 6448.
  • 19
    Nam RK,Sugar L,Wang Z,Yang W,Kitching R,Klotz LH,Venkateswaran V,Narod SA,Seth A. Expression of TMPRSS2 ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 2007; 6: 405.
  • 20
    Rajput AB,Miller MA,De Luca A,Boyd N,Leung S,Hurtado-Coll A,Fazli L,Jones EC,Palmer JB,Gleave ME,Cox ME,Huntsman DG. Frequency of the TMPRSS2: ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007; 60: 123843.
  • 21
    Wang J,Cai Y,Ren C,Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006; 66: 834751.
  • 22
    Kijima M,Yoshida M,Sugita K,Horinouchi S,Beppu T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 1993; 268: 2242935.
  • 23
    Cabrero JR,Serrador JM,Barreiro O,Mittelbrunn M,Naranjo-Suarez S,Martin-Cofreces N,Vincente-Manzanares M,Mazitschek R,Bradner JE,Avila J,Valenzuela-Fernandez A,Sanchez-Madrid F. Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity. Mol Biol Cell 2006; 17: 343545.
  • 24
    Hubbert C,Guardiola A,Shao R,Kawaguchi Y,Ito A,Nixon A,Yoshida M,Wang XF,Yao TP. HDAC6 is a microtubule-associated deacetylase. Nature 2002; 417: 4558.
  • 25
    Koeller KM,Haggarty SJ,Perkins BD,Leykin I,Wong JC,Kao MCJ,Schreiber SL. Chemical genetic modifier screens: small molecule trichostatin suppressors as probes of intracellular histone and tubulin acetylation. Chem Biol 2003; 10: 397410.
  • 26
    Chirco R,Liu XW,Jung KK,Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 2006; 25: 99113.
  • 27
    Peng Y,Chen L,Li C,Lu W,Chen J. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J Biol Chem 2001; 276: 4058390.
  • 28
    Bali P,Pranpat M,Bradner J,Balasis M,Fiskus W,Guo F,Rocha K,Kumaraswamy S,Boyapalle S,Atadja P,Seto E,Bhalla K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005; 280: 2672934.
  • 29
    Iljin K,Wolf M,Edgren H,Gupta S,Kilpinen S,Skotheim RI,Peltola M,Smit F,Verhaegh G,Schalken J,Nees M,Kallioniemi O. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 2006; 66: 102426.
  • 30
    Yang L,Mei Q,Zielinska-Kwiatkowska A,Matsui Y,Blackburn ML,Benedetti D,Krumm AA,Taborsky GJJr,Chansky HA. An ERG (ets-related gene)-associated histone methyltransferase interacts with histone deacetylases 1/2 and transcription co-repressors mSin3A/B. Biochem J 2003; 369: 6517.
  • 31
    Butler LM,Agus DB,Scher HI,Higgins B,Rose A,Cordon-Cardo C,Thaler HT,Rifkind RA,Marks PA,Richon VM. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000; 60: 516570.
  • 32
    Kuefer R,Hofer MD,Altug V,Zorn C,Genze F,Kunzi-Rapp K,Hautmann RE,Gschwend JE. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer 2004; 90: 53541.
  • 33
    Kulp SK,Chen CS,Wang DS,Chen CY,Chen CS. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res 2006; 12: 5199206.
  • 34
    Myzak MC,Tong P,Dashwood WM,Dashwood RH,Ho E. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med 2007; 232: 22734.
  • 35
    Qian DZ,Kato Y,Shabbeer S,Wei Y,Verheul HM,Salumbides B,Sanni T,Atadja P,Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 2006; 12: 63442.
  • 36
    Rephaeli A,Blank-Porat D,Tarasenko N,Entin-Meer M,Levovich I,Cutts SM,Phillips DR,Malik Z,Nudelman A. In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer. Int J Cancer 2005; 116: 22635.
  • 37
    Xia Q,Sung J,Chowdhury W,Chen CL,Hoti N,Shabbeer S,Carducci M,Rodriguez R. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 2006; 66: 723744.
  • 38
    Xu W,Ngo L,Perez G,Dokmanovic M,Marks PA. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA 2006; 103: 155405.